#USA #Boston #gene therapy #PackGene #AAV Manufacturing

PackGene Showcases AAV Advances at ASGCT 2026

PackGene Biotech, Inc., a frontrunner in AAV vector development, is gearing up to present its latest advancements at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Boston from May 11 to 15, 2026. The company is set to feature six key presentations that highlight its ongoing commitment to address significant challenges in scalable AAV manufacturing.

The presentations by PackGene will cover critical aspects of AAV vector production, including the reduction of residual DNA impurities, managing the variability between empty and full viral particles, and ensuring consistency in manufacturing. The agenda includes two oral talks and four poster displays, showcasing innovations in upstream processing, purification techniques, and capsid engineering designed to enhance targeting and increase safety in gene therapy applications.

Innovation Spotlight

Xin Swanson, Ph.D., the Chief Strategy Officer at PackGene, stated, "At PackGene, our mission is to make gene therapy more accessible. Our presentations this year emphasize our extensive innovations aimed at producing safer, higher-quality AAV vectors consistently and at scale. We are addressing key bottlenecks in AAV manufacturing with advancements in capsid designs and analytical methodologies that minimize DNA contamination, thereby elevating product quality. This is crucial for reliable outcomes in gene therapy."

Presentation Details

The highlights of PackGene’s ASGCT 2026 program include:

• - Oral Presentations (Location: MCEC Room 258ABC, Level 2)

- Advancing AAV manufacturing through process optimization and intensification
Presenter: Ran Li, Associate Director, Process Analytic Development
Date: May 13, 2026, at 9 a.m.
- Implementation of Upstream Mitigation Strategies to Minimize Residual Plasmid Backbone and Host Cell DNA Encapsidation in rAAV Vectors
Presenter: Amos Gutnick, Associate Director, Product Development
Date: May 14, 2026, at 9 a.m.

• - Poster Presentations (Location: MCEC Exhibit and Poster Halls B2-C, Exhibit Level)

- Decoupling Efficacy from Toxicity Engineering Spatial Control in AAV-Mediated Gene Therapy to Mitigate Hepatotoxicity
Poster Number: #2414
Date: May 14, 2026, from 5 to 6:30 p.m.
- A Fast Extraction-Free RT-qPCR Assay Utilizing Dual DNA/RNA Targeting for Rapid Mycoplasma Detection in CGT Products
Poster Number: #3215
Date: May 14, 2026, from 5 to 6:30 p.m.
- Establishment of Serotype-Specific rcAAV Reference Samples to Enhance Testing Sensitivity and Specificity for AAV Manufacturing
Poster Number: #3216
Date: May 14, 2026, from 5 to 6:30 p.m.
- Qualifying Mass Photometry Performance for AAV Empty/Full Ratio Measurement Using Native Reference Standards
Poster Number: #1217
Date: May 12, 2026, from 5 to 6:30 p.m.

All poster presentation abstracts will be accessible publicly through the ASGCT website. Additionally, attendees are encouraged to visit PackGene at booth 1531 for more information or to set up meetings with the team.

About PackGene

PackGene Biotech is recognized as a leading contract research organization (CRO) and contract development and manufacturing organization (CDMO), offering economical and reliable AAV vector production that spans from early discovery stages through clinical trials in cell and gene therapy. Their services include notable features like process development, GMP manufacturing, and robust analytical testing that ensure high-quality vector supply. Utilizing its proprietary π-Alpha 293 AAV High-Yield Platform, PackGene enhances AAV production by 3–8 times across various serotypes while applying Quality by Design (QbD) optimizations that can amplify the total yield up to 10 times. Their comprehensive platforms focus on both AAV and plasmid vectors, complemented by in-depth analytical development and quality assurance processes. For additional details about PackGene, please visit their website at PackGene.com.